Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Clinical trial NCT05488821 · UNKNOWN
Trial details
- NCT number
- NCT05488821
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-14
- Primary completion
- 2024-07-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.